Revolutionizing Personalized Medicine: Adaptive Biotechnologies Corp’s Business Update Conference Call and Webcast on April 2nd, 2024.

Adaptive Biotechnologies Corporation is a biotechnology company that has recently announced a business update conference call and webcast on April 2, 2024, after the market closes. The event will begin at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time and will be accessible through the “Investors” section of their website at www.adaptivebiotech.com.

Adaptive Biotechnologies believes that the adaptive immune system can be a powerful tool for diagnosing and treating diseases, but its complexity has limited its full utilization. The company’s immune medicine platform aims to decode and leverage the genetics of the adaptive immune system with scale, precision, and speed. They collaborate with biopharmaceutical companies, inform drug development, and develop clinical diagnostics in two main areas: Minimal Residual Disease (MRD) and Immune Medicine.

Their products and clinical pipeline focus on diagnosing, monitoring, and treating diseases like cancer, autoimmune disorders, and infectious diseases with the goal of creating personalized immune-driven clinical products for each patient. Adaptive Biotechnologies is committed to revolutionizing personalized medicine through its innovative platform that leverages the power of the adaptive immune system to improve patient outcomes.

For investors interested in Adaptive Biotechnologies, they can reach out to their Vice President of Investor Relations, Karina Calzadilla at 201-396-1687 or by emailing investors@adaptivebiotech.com